Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894890258> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2894890258 endingPage "40" @default.
- W2894890258 startingPage "34" @default.
- W2894890258 abstract "Background. Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a single agent or in combination with paclitaxel for treatment of advanced gastric or gastroesophageal junction adenocarcinoma that has progressed on or after prior fluoropyrimidineor platinum containing chemotherapy based on data of REGARD and RAINBOW trials. Materials and Methods : From June 2016 to 15Jan 201837 pts with advanced GC were treated with ramucirumabin the second line treatment as single agent (11 pts) or in combination with paclitaxel (26 pts) in N.N.Blokhin National medical research center of oncology. Results : edian PFS (MPFS) and median OS (MOS) was 1,8 and 7,6 mons for monotherapy group. For combination group MPFS was 4,0mons, MOS -10,6 mons. Ramucirumab had an acceptable safety profile Conclusions :ur data are similar to the data of international randomized trials." @default.
- W2894890258 created "2018-10-12" @default.
- W2894890258 creator A5013508173 @default.
- W2894890258 creator A5022911908 @default.
- W2894890258 creator A5028361014 @default.
- W2894890258 creator A5044208514 @default.
- W2894890258 creator A5049153893 @default.
- W2894890258 creator A5051970875 @default.
- W2894890258 creator A5052978985 @default.
- W2894890258 creator A5059463927 @default.
- W2894890258 creator A5059793527 @default.
- W2894890258 creator A5069395871 @default.
- W2894890258 creator A5074592838 @default.
- W2894890258 creator A5083909830 @default.
- W2894890258 creator A5086314799 @default.
- W2894890258 date "2018-07-19" @default.
- W2894890258 modified "2023-09-25" @default.
- W2894890258 title "Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia" @default.
- W2894890258 cites W1964032878 @default.
- W2894890258 cites W2097820456 @default.
- W2894890258 cites W2104631255 @default.
- W2894890258 cites W2104759721 @default.
- W2894890258 cites W2111237964 @default.
- W2894890258 cites W2114734455 @default.
- W2894890258 cites W2128328462 @default.
- W2894890258 cites W2132871418 @default.
- W2894890258 cites W2139248078 @default.
- W2894890258 cites W2171075804 @default.
- W2894890258 cites W2768121504 @default.
- W2894890258 doi "https://doi.org/10.21518/2079-701x-2018-10-34-40" @default.
- W2894890258 hasPublicationYear "2018" @default.
- W2894890258 type Work @default.
- W2894890258 sameAs 2894890258 @default.
- W2894890258 citedByCount "0" @default.
- W2894890258 crossrefType "journal-article" @default.
- W2894890258 hasAuthorship W2894890258A5013508173 @default.
- W2894890258 hasAuthorship W2894890258A5022911908 @default.
- W2894890258 hasAuthorship W2894890258A5028361014 @default.
- W2894890258 hasAuthorship W2894890258A5044208514 @default.
- W2894890258 hasAuthorship W2894890258A5049153893 @default.
- W2894890258 hasAuthorship W2894890258A5051970875 @default.
- W2894890258 hasAuthorship W2894890258A5052978985 @default.
- W2894890258 hasAuthorship W2894890258A5059463927 @default.
- W2894890258 hasAuthorship W2894890258A5059793527 @default.
- W2894890258 hasAuthorship W2894890258A5069395871 @default.
- W2894890258 hasAuthorship W2894890258A5074592838 @default.
- W2894890258 hasAuthorship W2894890258A5083909830 @default.
- W2894890258 hasAuthorship W2894890258A5086314799 @default.
- W2894890258 hasBestOaLocation W28948902581 @default.
- W2894890258 hasConcept C121608353 @default.
- W2894890258 hasConcept C126322002 @default.
- W2894890258 hasConcept C143998085 @default.
- W2894890258 hasConcept C2776694085 @default.
- W2894890258 hasConcept C2777292972 @default.
- W2894890258 hasConcept C2779551604 @default.
- W2894890258 hasConcept C2781182431 @default.
- W2894890258 hasConcept C71924100 @default.
- W2894890258 hasConcept C90924648 @default.
- W2894890258 hasConceptScore W2894890258C121608353 @default.
- W2894890258 hasConceptScore W2894890258C126322002 @default.
- W2894890258 hasConceptScore W2894890258C143998085 @default.
- W2894890258 hasConceptScore W2894890258C2776694085 @default.
- W2894890258 hasConceptScore W2894890258C2777292972 @default.
- W2894890258 hasConceptScore W2894890258C2779551604 @default.
- W2894890258 hasConceptScore W2894890258C2781182431 @default.
- W2894890258 hasConceptScore W2894890258C71924100 @default.
- W2894890258 hasConceptScore W2894890258C90924648 @default.
- W2894890258 hasIssue "10" @default.
- W2894890258 hasLocation W28948902581 @default.
- W2894890258 hasLocation W28948902582 @default.
- W2894890258 hasOpenAccess W2894890258 @default.
- W2894890258 hasPrimaryLocation W28948902581 @default.
- W2894890258 hasRelatedWork W1966838115 @default.
- W2894890258 hasRelatedWork W2053778437 @default.
- W2894890258 hasRelatedWork W2077655419 @default.
- W2894890258 hasRelatedWork W2155410413 @default.
- W2894890258 hasRelatedWork W2543282426 @default.
- W2894890258 hasRelatedWork W2769560527 @default.
- W2894890258 hasRelatedWork W2899545675 @default.
- W2894890258 hasRelatedWork W2983426905 @default.
- W2894890258 hasRelatedWork W3024197984 @default.
- W2894890258 hasRelatedWork W3041235120 @default.
- W2894890258 isParatext "false" @default.
- W2894890258 isRetracted "false" @default.
- W2894890258 magId "2894890258" @default.
- W2894890258 workType "article" @default.